FDA Reverses Decision on Rare Blood Cancer Drug, Cigna Expands with CarepathRx Acquisition

The FDA unexpectedly rejected a promising rare blood cancer therapy after initially showing support, highlighting regulatory uncertainties in drug approvals. Meanwhile, Cigna's acquisition of CarepathRx signals a strategic move into the hospital pharmacy sector, potentially shaping pharmaceutical distribution dynamics. These developments are crucial for stakeholders to monitor regulatory trends and market shifts in healthcare infrastructure.